<DOC>
	<DOCNO>NCT00254332</DOCNO>
	<brief_summary>This blood tissue study determine effect drug call denileukin diftitox immune system cell may involve patient response cutaneous t-cell lymphoma . Patients undergo standard care therapy denileukin diftitox invite participate . Blood tissue sample obtain baseline , day 5 day 19 first 4 cycle denileukin diftitox .</brief_summary>
	<brief_title>Effect Denileukin Diftitox Immune System CTCL Patients</brief_title>
	<detailed_description>Although etiology CTCL fully understand , believe malignancy proliferation `` memory '' T-cell context Th2-type cytokine profile suppress cytotoxic T-cell ( CTL ) immunity . T-regulatory ( T-regs ) cell may important CTCL setting immunotherapy . Removal T-regs would result enhance immune response vitro , may translate augmentation anti-tumor immune response durable clinical response vivo . We propose evaluate effect ONTAK T-reg cell subset patient undergoing routine therapy ONTAK . We evaluate T-reg subset peripheral blood tumor tissue patient phenotypically use multi-color FACS analysis confocal microscopy , functionally MLRs ELISpot assay baseline , day 5 19 blood sample four cycle . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>18 old diagnose CTCL able willing provide inform consent receive denileukin diftitox per standard guideline prior history receive Ontak pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Cutaneous T-cell Lymphoma</keyword>
	<keyword>Sezary Syndrome</keyword>
	<keyword>Mycosis Fungoides</keyword>
	<keyword>Denileukin Diftitox</keyword>
</DOC>